熱門資訊> 正文
Medirom将收购日本基因医学的多数股权
2024-07-11 04:34
- Medirom Healthcare Technologies (NASDAQ:MRM) on Wednesday said that it plans to acquire a 70% majority stake in Japan Gene Medicine.
- The company added that it had entered into a share transfer agreement on June 30, 2024.
- The total transfer consideration would amount to 2B yen, in which 350 shares of common stock of Japan Gene Medicine would be transferred.
- The company had also entered into a legally binding memorandum of understanding, to obtain an option to acquire the remaining 30% of Japan Gene Medicine.
- The company expects to finance the transaction using its own funds and borrowings.
- Press release.
More on MEDIROM Healthcare Technologies - ADS
- Financial information for MEDIROM Healthcare Technologies - ADS
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
